Brokerages Set Opthea Limited Unsponsored ADR (NASDAQ:OPT) Price Target at $1.33

Opthea Limited Unsponsored ADR (NASDAQ:OPT) has been given a consensus rating of “Hold” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $1.3333.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Opthea in a research note on Tuesday, October 14th.

Opthea Stock Up 7.2%

NASDAQ:OPT opened at $3.41 on Tuesday. Opthea has a fifty-two week low of $1.79 and a fifty-two week high of $6.30. The stock’s 50-day moving average is $3.41 and its two-hundred day moving average is $3.41.

Institutional Investors Weigh In On Opthea

Several large investors have recently made changes to their positions in the company. Regal Partners Ltd grew its stake in shares of Opthea by 78.6% in the 1st quarter. Regal Partners Ltd now owns 5,193,688 shares of the company’s stock valued at $17,710,000 after buying an additional 2,286,285 shares in the last quarter. Twin Lakes Capital Management LLC grew its stake in shares of Opthea by 67.4% in the 1st quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company’s stock valued at $113,000 after buying an additional 13,350 shares in the last quarter. OLD Mission Capital LLC grew its stake in shares of Opthea by 78.7% in the 1st quarter. OLD Mission Capital LLC now owns 19,167 shares of the company’s stock valued at $65,000 after buying an additional 8,439 shares in the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Opthea in the 1st quarter valued at approximately $34,000. Institutional investors own 55.95% of the company’s stock.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.